S-1/A: Nascent Biotech Seeks $3 Million in Public Offering to Fund Clinical Trials

Nascent Biotech aims to raise capital for Phase 2 clinical trials and administrative expenses through a self-underwritten public offering of 20,000,000 shares of common stock at $0.15 per share.

Summary

• Nascent Biotech has filed an amendment to its Form S-1/A registration statement for a proposed offering.
• The offering includes the potential sale of 20,000,000 shares of common stock by the company at a fixed price of $0.15 per share, aiming to raise $3 million.
• Additionally, the registration covers the resale of shares underlying convertible debentures (1,250,000 shares) and warrants (1,000,000 shares) held by selling security holders.
• The company intends to use the proceeds from its share sales to fund Phase 2 clinical trials of its drug and for general and administrative expenses.
• The offering is self-underwritten, with the company's directors attempting to sell the shares on a best efforts basis.
• The offering will terminate on the earlier of October 1, 2024, the date all 20,000,000 shares are sold, or when the Board decides to terminate the offering.
• The company's common stock is currently quoted on the OTCQB under the symbol NBIO, with the last reported sale price on March 11, 2024, at $0.15.
• The company is registering 10,000,000 shares of common stock held by a single shareholder who purchased the shares at $0.10 per share in September 2023.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive developments such as the clearance to begin Phase 2 clinical trials and the issuance of patents, the company's financial situation is concerning, with a history of losses, negative working capital, and a going concern warning from its auditors. The need for a capital raise further underscores the financial challenges.

Positives

• The company has been cleared to begin Phase 2 clinical trials for Pritumumab.
• The company has regained worldwide rights for development and distribution of Pritumumab.
• The company has two patents issued by the US Patent Office.

Negatives

• The offering price of $0.15 per share bears no relationship to the company's assets, book value, or earnings.
• The company has a history of operating losses and an accumulated deficit.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company's stock is considered a penny stock, which makes it more difficult for investors to sell their shares.

Risks

• Investing in the company's common stock involves a high degree of risk.
• The company currently has no product revenues and will need to raise additional capital to operate its business.
• The company's stock price may be volatile.
• The company may issue additional shares of common stock in the future, which would reduce investors' ownership interests and dilute share value.
• FINRA sales practice requirements may limit a stockholder's ability to buy and sell the company's stock.

Future Outlook

The company expects to incur substantial losses and negative operating cash flow for the foreseeable future as it commences clinical trials of its drug candidates, which it does not expect will be commercially available for several years, if at all.

Industry Context

The development and commercialization of new products to treat cancer is highly competitive, and the company expects considerable competition from major pharmaceutical, biotechnology and specialty cancer companies.

Related Party Transactions

• The company has entered into compensation agreements with its officers and directors, issuing shares of common stock to maintain their ownership percentage.
• During the year ended March 31, 2023, the company issued 3,815,414 shares of common stock with a value of $624,320 to three related parties for services.

Stakeholder Impact

• The offering of common stock may dilute the ownership interests of existing stockholders.
• The company's ability to continue as a going concern is dependent on its ability to raise additional financial support.
• The company's success in developing and commercializing its drug candidates will impact the value of its stock and the returns to its investors.

Next Steps

• Commence Phase II clinical trials in the United States with Pritumumab.
• Continue to evaluate the application of Pritumumab in the treatment of other unmet ectodomain vimentin positive cancer types such as pancreatic.

Key Dates

Keywords

common stock, clinical trials, Pritumumab, offering, Nascent Biotech, biotech, shares, debt